Unique T-lymphocyte line and products derived therefrom
Glycoproteins and processes for their production
Process for producing target cell lysis factor and uses therewith Patent #: 4495282
ApplicationNo. 06/675291 filed on 11/27/1984
US Classes:514/8, Glycoprotein (carbohydrate containing)435/70.4, Blood (lymphoid) cell culture530/351Lymphokines, e.g., interferons, interlukins, etc.
ExaminersPrimary: Hazel, Blondel
Attorney, Agent or Firm
International ClassesC07K 16/18 (20060101)
C07K 14/435 (20060101)
C07K 14/52 (20060101)
C07K 16/24 (20060101)
A61K 38/00 (20060101)
A61K 39/00 (20060101)
Foreign Application Priority Data1983-12-13 JP
AbstractDisclosed is an invention relating to a novel lymphokine and to the production and uses thereof. The invention also relates to a monoclonal antibody specific to the lymphokine and its production. The novel lymphokine is a glycoprotein having a molecular weight of 20,000b1;2,000 daltons; isoelectric point pI, 5.6b1;0.2; electrophoretic mobility Rf, 0.29b1;0.02; and cytotoxic on a mouse cell line L 929. The lymphokine inhibits significantly the growth of malignant human tumors in vivo. The monoclonal antibody is IgM or IgG class, and neutralizes specifically the cytotoxic activity of the lymphokine.
Field of SearchLymphokines, e.g., interferons, interlukins, etc.